- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response - - Data represent the first demonstration of PROTAC ®-mediated degradation ...
Arvinas is pushing ahead with plans to expand development of its prostate cancer prospect ARV-766 into earlier-line settings. The biotech linked the protein degrader to declines in the PSA biomarker ...
– 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA 50; in patients with AR L702H mutations, 3 of 5 achieved PSA 50 – – ARV-766 was well-tolerated, and activity in a heavily ...
– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated ...
Many widely used oncology therapies work by inhibiting cancer-related proteins. But what if we simply destroyed those proteins rather than trying to block their functions? That’s the idea behind the ...
NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results